Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolic Solutions Development Company (MSDC) has received a $1.1m grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH), to assess MSDC-0602 in treating fatty liver disease (FLD).
Subscribe to our email newsletter
MSDC-0602, an insulin sensitizer is selective for a molecular target, mTOT, which connects mitochondrial metabolism to important cell functions.
Recent Phase 2a study in patients suffering with type 2 diabetes demonstrated that MSDC-0602 significantly controlled the glucose level and increased insulin sensitivity.
Preclinical studies in a rodent model of FLD funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) also showed that MSDC-0602 improved insulin sensitivity and the ability of the liver to oxidize and clear fat.
MSDC CEO Stephen Benoit said the mTOT biochemical pathway will enable their researchers to select compounds that treat the root cause of various health issues affecting Americans today.